WG
ICPT

Winton Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Winton Group’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-22,620
Closed -$304K – 1187
2023
Q1 		$304K Buy
22,620
+1,897
+9% +$32.8K 0.02% 819
2022
Q4 		$256K Buy
20,723
+885
+4% +$12.5K 0.02% 818
2022
Q3 		$277K Sell
19,838
-2,422
-11% -$39K 0.02% 819
2022
Q2 		$307K Buy
22,260
+4,900
+28% +$78.5K 0.02% 801
2022
Q1 		$282K Buy
17,360
+3,486
+25% +$54.6K 0.01% 833
2021
Q4 		$226K Buy
+13,874
New +$234K 0.01% 918
2021
Q3 		– Sell
-15,664
Closed -$313K – 1512
2021
Q2 		$313K Buy
15,664
+3,101
+25% +$61.5K 0.02% 1155
2021
Q1 		$290K Buy
+12,563
New +$350K 0.02% 1156

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Winton Group's ICPT Position: Q2 2023 in Review

Winton Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2023, closing a stake of 22,620 shares — an estimated $304K sold.

Winton Group first reported a position in ICPT in Q1 2021 and held it in 8 quarters. The position peaked at $313K in Q2 2021. 126 funds tracked by Wall St. Rank hold ICPT as of Q2 2023.

  • Winton Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Winton Group sold 22,620 Intercept Pharmaceuticals, Inc. shares in Q2 2023, an estimated $304K.
  • Winton Group first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2021 and held it in 8 quarters.
  • Winton Group's Intercept Pharmaceuticals, Inc. position peaked at $313K in Q2 2021.
  • 126 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2023.

Based on Winton Group's 13F filing for Q2 2023, filed 14 Aug 2023.